Table 1.
Clinicopathologic characteristics
| T-bet+ | T-bet− | p value | |
|---|---|---|---|
| N = 67 (27.7%) | N = 175 (72.3%) | ||
| Age at diagnosis | |||
| Mean (range) | 58.2 (32–86) | 60.8 (30–89) | 0.16a |
| Tumor size | |||
| T1a/b (≤ 1 cm) | 6 (8.9%) | 14 (8.0%) | 0.04 b |
| T1c (> 1 cm, ≤ 2 cm) | 42 (62.7%) | 79 (45.1%) | |
| T2 (> 2 cm, ≤ 5 cm) | 19 (28.4%) | 75 (42.9%) | |
| T3 (> 5 cm) | 0 | 7 (4.0%) | |
| Nodal status | |||
| N0 | 44 (65.7%) | 118 (67.4%) | 0.62b |
| N1 (1–3) | 19 (28.3%) | 39 (22.3%) | |
| N2 (4–9) | 2 (3.0%) | 11 (6.3%) | |
| N3 (≥ 10) | 2 (3.0%) | 6 (3.4%) | |
| Unknown | 1 (0.6%) | ||
| Pathological stage | |||
| I | 31 (46.3%) | 71 (40.6%) | 0.33b |
| II | 33 (49.2%) | 86 (49.1%) | |
| III | 3 (4.5%) | 18 (10.3%) | |
| Nuclear grade | |||
| 1 + 2 | 5 (7.5%) | 65 (37.2%) | < 0.0001 b |
| 3 | 58 (86.5%) | 107 (61.1%) | |
| Unknown | 4 (6.0%) | 3 (1.7%) | |
| Ki-67 (%) | |||
| ≤ 30 | 3 (5.8%) | 45 (29.0%) | < 0.0001 b |
| > 30 | 57 (80.6%) | 104 (57.9%) | |
| Unknown | 7 (13.6%) | 26 (13.1%) | |
| CD8 | |||
| Negative | 12 (17.9%) | 103 (58.9%) | < 0.0001 b |
| Positive | 55 (82.1%) | 72 (41.1%) | |
| PD-L1 on tumor cells | < 0.0001 b | ||
| Negative | 22 (32.8%) | 121 (69.1%) | |
| Positive | 45 (67.2%) | 54 (30.9%) | |
| Surgical treatment | |||
| Breast-conserving surgery | 50 (74.6) | 94 (53.7) | 0.003 b |
| Mastectomy | 17 (25.4) | 81 (46.3) | |
| Adjuvant treatment | |||
| Chemotherapy | 50 (74.6%) | 117 (66.8%) | 0.27b |
| No treatment | 17 (25.4%) | 57 (32.6%) | |
| Unknown | 0 | 1 (0.6%) | |
Bold value represents that P value was significant
aLogistic regression
bPearson’s χ2 test